GlassScriptPhysician profile
Todd M Rosenthal
NPI 1831484302
$4,055.70
in general payments reported to CMS, 2019-2025
31 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $162 · 2021: $146 · 2022: $252 · 2023: $805 · 2024: $888 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $661.44 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $295.21 | 2021-2025 | Verquvo |
| Abbott Laboratories | $288.94 | 2019-2024 | Cardiomems |
| Pfizer INC. | $287.59 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $276.70 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $273.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $199.33 | 2019-2025 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $197.68 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $161.95 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $156.74 | 2019-2023 | |
| Edwards Lifesciences Corporation | $150.31 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.31 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $107.43 | 2023-2025 | Nexletol |
| Novo Nordisk INC | $90.51 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Azurity Pharmaceuticals, INC. | $85.25 | 2023-2024 | Edarbyclor, Edarbi, Edarbyclor |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $84.81 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.49 | 2019-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $79.96 | 2024 | Arcalyst |
| Baxter Healthcare | $49.59 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $47.91 | 2022-2025 | Onpattro |
| Bridgebio Pharma, INC. | $47.14 | 2025 | Attruby |
| Cvrx, INC. | $45.41 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $40.09 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $39.19 | 2022-2023 | Arcalyst |
| Boston Scientific Corporation | $36.09 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $33.75 | 2024 | |
| Lundbeck LLC | $28.83 | 2019 | |
| Cleerly, INC. | $19.52 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Kowa Pharmaceuticals America, INC. | $14.89 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Rosenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.